Joost Peerbooms

74 Chapter 5 Figure 3. Twenty-five of the 49 patients (51%) in the corticosteroid (CS) group and 37 of the 51 patients (73%) patients in the platelet-rich plasma (PRP) group were defined as successful with the DASH Outcome Measure, a significant difference (P = .005). CI, confidence interval. One year after the procedure, PRP-treated patients reported a mean improvement of 63.9% (70.1 to 25.3) in their VAS scores compared with the initial values, whereas the corticosteroid-treated patients reported a 24.0% improvement (65.8 to 50.1; P < .001) (Figure 2). Also, after 1 year, DASH scores improved 66% (161.3 to 54.7) in PRP patients versus a 17.4% improvement (131.3 to 108.4) in corticosteroid-treated patients ( P = .001) (Figure 3). Regarding the patients who failed their treatment, those who crossed over to the PRP group and those who received surgery did finally benefit. The patients who received a